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Abstract: This review focuses on connexins and nexus or gap junctions in the genesis, progression,
and therapy of carcinomas of the human urinary tract. Some decades ago, the idea was born that
gap junctional intercellular communication might prevent both the onset and the progression of
cancer. Later evidence indicated that, on the contrary, synthesis and the presence of connexins as a
prerequisite for gap junctional intercellular communication might promote the occurrence of cancer
and metastases. The research history of urinary bladder cancer is a good example of the development
of scientific perception. So far, the role of gap junctional intercellular communication in carcinogenesis
and cancer progression, as well as in therapeutical approaches, remains unclear.
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cancer; carcinogenesis
1. Introduction
Gap junctions facilitate intercellular communication and regulate proliferation and
differentiation [1]. Since gap junctional intercellular communication (GJIC) is necessary to mediate
contact inhibition in growing cells and tissues, inhibited GJIC might reduce growth control and
differentiation [2] and is a hallmark of epithelial-derived cancer cells [3]. James Trosko stated that
epigenetic tumor promoters and activated oncogenes can block gap junction function and yield insights
into the complex [2]. Gap junctions are formed by two connexons or hemichannels of neighboring cells.
These hemichannels are made up of six subunits of connexins. At total of 21 different connexins are
known in humans [4–6] and these are named according to their approximate molecular weight. The
typical morphology of a gap junction is shown in Figure 1. To achieve such photographs of gap junction
ultra-structures with transmission electron microscopy, a special technique, namely the freeze-fracture
technique, is necessary [7,8]. Gap junctions are channels which bridge two separate cells, enablingions,
second messenger signals, and other molecules (<1kD) to reach the cytoplasm of adjacent cells [9,10].
A prime example is the intercalated discs in the heart muscle, where connexins form gap junctions and
enable the distribution of calcium to spread the excitation from pace maker nodes to all parts of the
heart [11]. In their general contribution to intercellular communication, connexins and gap junctions
also regulate proliferation and cellular differentiation [1,12].
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the urethra. Closely related epithelial organs, such as prostate and seminal vesicles, which are 
necessary for reproduction, are also included in this context. In general, gap junctions have rarely 
been reported in the healthy human urinary tract at all; these reports will be summarized at the end 
of the review. Most information is available for the human urinary bladder: Gap junctions, mainly 
connexin 43, were found in the smooth muscle cells of the detrusor muscle of the urinary bladder 
[16]. Connexin 43 has additionally been detected in interstitial cells, which are located close to the 
epithelium [17]. The epithelium of the human urinary tract, which is called the urothelium, was found 
to b  negative for connexins 40, 43, and 45. In contrast, connexin 43 has been detected in the urothelial 
layer of the bovine urinary bladder and its cancer [18]. 
 
Figure 1. Freeze-fracture image of a gap junction in the myelin sheath of an optical nerve axon 
(mouse), consisting of P-face (the P-face, close to protoplasm, is the inner lamella of the plasma 
membrane viewed from outside the cell; deep blue) particles and E-face (the E-face, close to the 
extracellular space, is the outer lamella of the plasma membrane viewed as if from within the cell; 
pale blue) pits, surrounded by tight junctions (yellow) and caveolae (green ‘C’s). Underlying myelin 
layer in pale red. Scale bar depicts 0.1 µm. 
2. Kidney and Renal Cell Carcinoma 
While data sets on the expression of different connexins within kidney epithelial cells—mostly 
compiled in cell lines—are limited, data on gap junctions within kidney tissues are even rarer. Gap 
junctions have been reported on the lateral membranes of cells of proximal tubules of human fetal 
kidneys [19]. Wilgenbus and colleagues have presented data on the expression of Cx26, Cx32, and 
Cx43 in normal kidney tissue and in carcinomas of kidney, prostate, and testis, but also of liver, 
breast, esophagus, skin, lung, and uterus [20]. In the kidney, they found immunoreactivity for Cx26 
and Cx43 in the epithelium of proximal tubules. A subtle signal for Cx43 was detected in three renal 
cell carcinomas in the same study. To our knowledge, no data are available on gap junctions in renal 
Figure 1. Freeze-fracture image of a gap junction in the myelin sheath of an optical nerve axon (mouse),
consisting of P-face (the P-face, close to protoplasm, is the inner lamella of the plasma membrane
viewed from outside the cell; deep blue) particles and E-face (the E-face, close to the extracellular
space, is the outer lamella of the plasma membrane viewed as if from ithin the cell; pale blue) pits,
surrounded by tight junctions (yellow) and caveolae (green ‘C’s). Underlying myelin layer in pale red.
Scale bar depicts 0.1 µm.
Th contribution of gap juncti ns and nexus to intercellular communication has been the subject of
heated discussions in the field of carcinogenesis. Highlighted are the interesting overviews presented
by Aasen et al. and Graham and colleagues [13,14]. Observations of connexins and gap junctions in
tumors are abundant, and their possible role, both in carcinogenesis and as targets for cancer therapy,
are broadly discussed [4,15]. The following section focuses on findings and hypotheses relating to
the different parts of the urinary tract and its carcinomas. The urinary tract consists of organs which
produce and control urine: The kidneys, the ureter, the urinary bladder, and the urethra. Closely
related epithelial organs, such as prostate and seminal vesicles, which are necessary for reproduction,
are also included in this context. In general, gap junctions have rarely been reported in the healthy
human urinary tract at all; these reports will be summarized at the end of the review. Most information
is available for the human urinary bladder: Gap junctions, mainly connexin 43, were found in the
smooth muscle cells of the detrusor muscle of the urinary bladder [16]. Connexin 43 has additionally
been detected in interstitial cells, which are located close to the epithelium [17]. The epithelium of the
human urinary tract, which is called the urothelium, was found to be negative for connexins 40, 43,
and 45. In contrast, connexin 43 has been detected in the urothelial layer of the bovine urinary bladder
and its cancer [18].
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2. Kidney and Renal Cell Carcinoma
While data sets on the expression of different connexins within kidney epithelial cells—mostly
compiled in cell lines—are limited, data on gap junctions within kidney tissues are even rarer. Gap
junctions have been reported on the lateral membranes of cells of proximal tubules of human fetal
kidneys [19]. Wilgenbus and colleagues have presented data on the expression of Cx26, Cx32, and
Cx43 in normal kidney tissue and in carcinomas of kidney, prostate, and testis, but also of liver, breast,
esophagus, skin, lung, and uterus [20]. In the kidney, they found immunoreactivity for Cx26 and
Cx43 in the epithelium of proximal tubules. A subtle signal for Cx43 was detected in three renal
cell carcinomas in the same study. To our knowledge, no data are available on gap junctions in
renal carcinoma. As mentioned above, there are more studies which have analyzed the expression of
connexins in cultured human tubule cells, such as, for instance, in cells of the proximal tubule [21].
In that study, “aggregates thought to represent gap junctions” [21], were presented in images of
freeze-fracture replicas and cells were shown to be functionally connected by electrophysiology. In
kidney cell lines, gap junctional intercellular communication (GJIC) was mostly investigated by dye
transfer assays, such as scratch labelling, e.g., by Noguchi et al. In one renal cancer cell line, they
detected a decreased expression of Cx43 and correspondingly reduced GJIC, whereas in another line, no
Cx43 expression at all, corresponding to the complete absence of GJIC, was measurable [22]. The same
group reported that all-trans retinoic acid enhanced GJIC between carcinogen-treated renal epithelial
cells [23]. Another interesting member of the connexin family is connexin 32 [24]. Connexin 32 was
found to be involved in a number of inherited neuropathies and especially in the Charcot-Marie-Tooth
disease [25,26]. In addition, a role in tumorigenesis has been described for this connexin [27]. The group
led by Yano published several studies on the role of connexin 32 in renal cell carcinoma and claimed
that connexin 32 regulates “proliferation, invasion, and metastasis” in renal cell carcinoma [28,29]. A
more recent report demonstrated that induction of the connexin 32 gene in human renal carcinoma
cells enhanced the vinblastine-induced cytotoxicity in human renal carcinoma cells [30].
3. Renal Pelvis, Ureter, and Urethra and Their Carcinomas
It is difficult to find specific data for the renal pelvis, the ureter, and the urethra. Connexin
26 has been detected in human urothelium of the urinary bladder using immunohistochemistry on
paraffin sections with limited expression in the basal layer. It is not unlikely that this is also true for
the urothelium in the renal pelvis, the ureter, and the urethra [31]. One report investigated urethral
tissue of rats and sheep [32]. The authors found a positive immunofluorescence for connexin 43 in
the urethral urothelium of sheep but not in that of rats. In contrast, the smooth muscle layer was
positive for connexin 43 in both species. In the same study a weaker signal was found for connexin
37 in the smooth muscle cells. As far as the authors are aware, no information is available on gap
junctions in the normal urothelium of the upper urinary tract and its tumors. Cancer of the upper
urinary tract is rare but has been described [33,34]. A main risk factor for urothelial carcinomas and
small cell neuroendocrine carcinomas in the urinary bladder and in the urinary tract in general is
tobacco smoking or exposure to tobacco smoke, respectively [35]. The assumption seems feasible that
many findings described for urinary bladder carcinomas are also true for the urinary tract in general,
including the renal pelvis and the ureter, dealt with in the following chapter.
4. Urinary Bladder and Urinary Bladder Carcinoma
Urinary bladder cancer is among the 15 most common cancers worldwide. It has a higher incidence
in Europe, North America, and Australia and a lower incidence in the Far Eastern countries [36]. More
than 400,000 new cases were counted in 2012. Urinary bladder cancer is the 5th most commonly
diagnosed cancer in Europe. Its incidence increases with age and it is most common between the
60th and 70th year of life. More men than women are affected. Exposure to tobacco smoke is the
main risk factor [36,37]. In the human bladder gap junctions, connexin 43 has been found in cells of
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the detrusor muscle [16]. The gap junction protein connexin 43 has also been detected in so-called
interstitial cells beneath the urothelium, and human urothelium was found to be a negative for
connexin 40, 43, and 45 [17]. In contrast, connexin 43 has been detected in the bovine urothelium
and partly in its tumors [18]. Interestingly, limited expression of connexin 26 has been detected in
human urothelium [31]. That report also revealed an altered, weakened expression of connexin 26 in
bladder tumors. An overview on the occurrence of gap junction proteins in the different anatomical
layers of the normal human urinary bladder and its carcinomas is presented in a schematic drawing
(Figure 2). A possible role of gap junctions and connexins in carcinogenesis was discussed for several
years [38,39]: The hypothesis was that a loss of connexins and reduced gap junctional intercellular
communication correlated to malignancy and the induction of connexins and gap junctions should
therefore be beneficial to patients suffering from urothelial carcinoma. In contrast, a converse theory
is that enhanced gap junctional intercellular communication or increased expression of connexins
promotes urinary bladder carcinogenesis [40]. The expression of connexins in human bladder cancer
has been investigated previously [31,41,42]. The investigations of Gee et al. showed the expression of
connexin 26 in urinary bladder cancer tissue and cells [31]. A further report by Gee et al. dealt with the
treatment of this cancer by deleting the expression of connexin 26 using a gene therapy approach [43].
In the study conducted by Comberg et al., the synthesis of a range of connexins (26, 29, 32, 36, and 43)
was investigated using immunohistochemistry on tissue samples of human urothelial carcinoma from
nine patients with urothelial carcinoma (5 males, 4 females). A major advantage of an approach using
immunohistochemistry is that specific labelling can be assigned to tumor cells or, if applicable, to other
tissues, such as interstitial cells, fibrocytes, or muscle cells. Slides were immune-stained with polyclonal
antibodies for connexins 26, 29, 32, 36, and 43. Connexin 26 was found in the tumor cells of two of the
nine patients. The connexins 29, 32, and 36 were not found in the tumor cells at all. In contrast, connexin
43 was detected in the tumor cells of 8 of the nine patients. It can be concluded from the results in this
report that connexins 29, 32, and 36 are unlikely to play a role in human urothelial carcinoma. The
main result of this study was that connexin 43 was frequently found in human urothelial carcinomas.
Examples of connexin 43 staining using immunohistochemistry was presented showing the typical
intercalating discs in tissue of the heart muscle (Figure 3A) and in tissue of a urinary bladder carcinoma
(Figure 3B). This supported data from another report on the synthesis or expression of connexin 43 in
urinary bladder carcinomas [42]. These authors found frequent expression levels of connexin 43 in
(non-muscular) invasive bladder cancer (NMIBC). In addition, high expression levels were associated
with a poor prognosis. They even proposed a routine assessment of connexin 43 expression to identify
high-risk NMIBC. Since normal human urothelium does not produce connexin 43, the presence of
connexin 43 may be tumor-specific or at least somehow tumor-associated. More than one decade ago
it was assumed that a loss of connexin 43 led to malignancy and that it might, therefore, be a target
for genetic therapeutical approaches [38,39]. As already mentioned, the more recent interpretation
of its role is exactly the opposite, i.e., connexin 43 expression promotes carcinogenesis in urinary
bladder carcinoma [44]. Connexin 43 enhances the adherence of tumor cells to the stroma as well as the
migration and, probably, the dissemination of cancer cells. Interestingly, one of the early evaluations
did actually also postulate that “increased gap junctional intercellular communication capacity or
increased connexin(s) expression” increased rat bladder carcinogenesis, as tested in cell lines and
tumors [40]. The high prevalence of the expression of connexin 43 in the studies of Poyet et al. and
Comberg et al. support the latter view [41,42]: The synthesis of connexin 43 in urothelial cancer cells is
more likely to be a co-factor in the genesis and growth of urothelial carcinomas than a physiological
or protecting factor. This view is supported by recent findings in prostate cancer, where connexins
were found to play a role in the dissemination of cancer cells [45]. Another interesting question is the
formation of gap junctions in the human urinary bladder and human urinary bladder cancer. With the
exception of indirect findings, using calcium flux experiments [46], there are only two publications to
be found which present gap junctions, using morphological techniques, such as electron microscopy.
One is the report of John et al. who found “small and irregularly shaped” gap junctions in the detrusor
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muscle of a non-obstructed human bladder using freeze-fracture studies [16]. Freeze-fracture studies
are a useful tool in the identification of gap junctions. However, a combination with immunolabelling
would be much more efficient as it would enable the visualization of the molecular assembling of
cancer-associated gap junctions [8]. The second is an older report by Alroy et al. who found “few and
small” gap junctions within primary adenocarcinoma of the human urinary bladder [47]. As can be
seen, the role of gap junctions in the context of human urinary bladder cancer is difficult to assess and
offers a wide and open field for further research.Cancers 2019, 11, x 5 of 13 
 
 
Figure 2. Schematic drawing of the layers and tumor distribution in the human urinary bladder and 
its cancer. The question marks relating to the expression of connexins in the various layers on the left 
side are answered, and, on the right side, are answered where possible. Finally, there are indications 
that connexons and gap junctions are present in the detrusor muscle and adenocarcinoma of the 
human urinary bladder. (orange = healthy prostate, blue carcinoma, 1 = urothelium, 2 = lamina 
propria and to some extent submucosa, 3 = detrusor muscle inner layer, 4 = detrusor muscle outer 
layer, 5 = adventitia). 
Figure 2. Schematic drawing of the layers and tumor distribution in the human urinary bladder and its
cancer. The question marks relating to the expression of connexins in the various layers on the left side
are answered, and, on the right side, are answered where possible. Finally, there are indications that
connexons and gap junctions are present in the detrusor muscle and adenocarcinoma of the human
urinary bladder. (orange = healthy prostate, blue carcinoma, 1 = urothelium, 2 = lamina propria
and to some extent submucosa, 3 = detrusor muscle inner layer, 4 = detrusor muscle outer layer, 5 =
adventitia).
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Figure 3. Representative microphotographs show the specific labeling of connexin 43 in the heart (A). 
The intercalated disks which express connexin 43 are labeled with a brown dye. A weaker but clear 
expression of connexin 43 can be observed on a section of a human urinary bladder cancer (B). 
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5. Prostate and Seminal Vesicles and Their Carcinomas
A recent review described connexins as important players in the dissemination of prostate cancer
cells [45]. Are there connexins and gap junctions in healthy prostate tissue? The expression of
connexin 32 was detected in the human prostatic epithelium [48]. In the same study, a dye transfer was
observed between cells of the normal human prostatic epithelium and those of prostate cancer cell
lines suggesting gap-junctional communication in both normal and malignant prostate cells. However,
the dye transfer was reduced in the malignant cells and not present in certain malignant cells. This
observation correlates with an observation made in a study analyzing tissues of prostate cancers. Here,
connexin 43 expression was reduced or even missing in prostate cancer tissues [49]. The same study
reported that, in contrast, an overwhelmingly high expression of connexin 43 was found in prostate
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tissue of patients suffering from benign prostate hyperplasia. This is an interesting finding, since
an expression of connexin 43 is not reported within the normal prostatic epithelium and is strongly
reduced in prostatic carcinomas. The assumption seems feasible that this indicates a continuum in the
biology of prostatic epithelium from differentiation over hyperplasia to de-differentiation and, finally,
to cancer. The increased expression in hyperplasia might be an epiphenomenon but, on the other hand,
it is more likely that connexin 43 is required in tissues with accelerated cell proliferation [50,51]. The
seminal vesicles are often invaded by carcinomas, such as the prostate carcinoma. The primary seminal
vesicle carcinoma is a rare disease [52]. Interestingly, the expression of connexins in human seminal
vesicles has not been investigated so far, but connexin 32 has been found in the seminal vesicles of
adult Sprague Dawley rats [53].
6. Urinary Tract Carcinomas, Related Toxic Agents and Connexons, Gap Junctions, and Gap
Junctional Intercellular Communication
It is well known that, whether in a personal or an occupational environment, exposure to toxic
agents, such as tobacco smoke and its ingredients, arsenic, cadmium, and aromatic amines, and further
substances, promote the development of carcinomas in the urinary tract—sometimes after a couple
of years, or even decades [37]. Do these agents have any influence on the structure and function of
gap junctions? To start with: Tobacco smoke. James Trosko et al. reported the inhibition of GJIC by
1-methylanthracene, a component of tobacco smoke [3]. A scrape loading/dye transfer technique,
which had been developed earlier by the same group, was applied to a cell line derived from rat
liver (WB-F344) [54]. They found that a distinct phospholipase C was important for the inhibition of
GJIC and non-mitogen-activated protein kinases, as previously assumed. This group also observed
interesting effects of tobacco smoke components in experiments using an epithelial cell line, derived
from the human pancreatic duct [55]. In a scrape loading assay the vulnerated cells were loaded
with Lucifer Yellow and the dye was detected in neighboring cells, the most obvious explanation of
which is by way of intercellular channels, such as gap junctions. A distinct component of tobacco
smoke, 1-methylanthracene with “bay-like structures”, inhibited the transfer of the dye. Another group
compared the effect of tobacco smoke components with primarily heated tobacco [56]. Human airway
epithelial cells, coronary artery endothelial cells, keratinocytes, and the above-mentioned rat liver
epithelial cell line were studied using fluorescence redistribution after photobleaching; the so-called
fluorescence recovery after photobleaching (FRAP) technique. In contrast to the previously described
technique, all cells were loaded with a fluorescent dye and the neighboring cells of a determined cell
were bleached using a laser beam. Interestingly, the heated tobacco did not inhibit GJIC between the
tested human cells, whereas components released from burned tobacco at equivalent concentrations
did inhibit the intercellular communication. An additional observation made in this same study was
that, in contrast to burned tobacco, the heated tobacco did not affect the release of lactate dehydrogenase
(LDH). This indicates that heated tobacco creates a lower level of cell toxicity than burned tobacco.
So-called dye-coupling, or parachute assays, have been performed using dye-loaded donor cells and
non-loaded acceptor cells [57]. This assay clearly demonstrated that the condensate of tobacco smoke
or tobacco smoke-derived particles, respectively, clearly decreased the transfer of the fluorescent dye
from donor to acceptor cells [58]. Cells derived from the epithelial cell line (WB-F344) of a rat liver
were prepared as donor cells and loaded with a dye. A transfer of intracellular fluorescent calcein
from donor cells to neighboring cells was determined. After subtraction of stained donor cells, the
percentage of stained cells represented the proportion of GJIC. Calcien can enter the membranes of
intact cells and minimize cellular stress [58]. Tobacco smoke-derived particles from cigarettes inhibited
the dye transfer, and thus that of GJIC, and concentrations of approx. 0.02 mg/mL and above were
measured. In tobacco smoke-derived particles, however, a half-maximal effective concentration of
approx. 0.05 mg/mL was established. The authors assumed that a major impact of polycyclic aromatic
hydrocarbons (PAHs) was responsible for the inhibition of the observed GJIC. Interestingly, arsenic
disrupts the molecular structure of connexin 43 and interrupts GJIC, which might contribute to the
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toxicity and carcinogenicity of arsenic [59]. Cadmium or cadmium salts, respectively, also inhibit
the gap junction-mediated communication between rat liver cells (cell line BRL 3A), as shown in a
scrape loading assay [60]. Cadmium and GJIC were investigated using a parachute assay in prostate
cells [61]. A low dose of CdCl2 stimulated cell proliferation, increased the expression of connexin 43,
and reduced the dye transfer between donor and acceptor cells by half. Aromatic amines, such as
aniline, toluidine, or naphthylamine, and others are important occupational toxic agents, for instance
in the chemical industry, but they are also components of tobacco smoke, drugs, pesticides, hair tinting
lotions, and other products [62]. So far, these aromatic amines have not been reported to represent
strong risk factors for urinary bladder carcinomas on GJIC. Interestingly, catechins, as ingredients
of green teas, have displayed positive effects in experiments using renal epithelium, which was
treated with nitrosamines [63]. In this study the pre-treatment with a distinct catechin ameliorated the
reduction of connexin 43 expression and GJIC. The authors suggest a “chemo preventive” effect of
green tea. Another relevant player is lipopolysaccharide (LPS), which is part of tobacco smoke or is
released during bacterial infections. LPS has effects on GJIC and the presence of connexins, e.g. down
regulation of connexin 43 and GJIC in astrocytes [64,65].
7. Putting it Together
Gap junctions have a crucial role in carcinogenesis in general, but especially in epithelia of the
human urinary tract. Endogenous, but even, to a greater extent, exogenous, environmental factors
trigger the epigenetic limb of pro-carcinogenic mechanisms, which often lead over years and decades to
carcinomas (Figure 4). So far, as investigated and reported, the connexins 26, 32, and mostly connexin
43, play a relevant role (Figure 4). From the published data, a cautious conclusion can be drawn that
connexin 26 is expressed and functionally active in the urothelium and the tubular epithelia. Connexin
32 was reported within the tubular and the prostate epithelia. Connexin 43 seems to be upregulated in
the tubular epithelia and in the urothelium of the urinary bladder, if hyperplasia and carcinoma occurs.
Data on GJIC and its modulation are available, but there remains a knowledge gap with regard to the
descriptive morphology of gap junctions in the tissues of the human urinary tract. From the authors´
point of view, this central question has yet to be addressed. Gap junctional intercellular communication
is without doubt involved in physiology, pathophysiology, carcinogenesis, and carcinoma growth and
metabolism. However, the available data do not allow conclusive judgement as to whether connexins,
connexons, and gap junctions promote or inhibit the development of carcinomas within the human
urinary tract. It is not unlikely, that in the case of an established carcinoma, the GJIC is recruited from
the cancer tissue to promote growth and vascularization. If that is the case, inhibiting approaches or
the destruction of structural components could be beneficial to patients. Thus, GJIC in cancers of the
urogenital tract remains a field wide open to research.
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In conclusion, distinct connexins and related molecules, pannexins, play a role in tumorigenesis 
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8. Concluding Remark
In conclusion, distinct connexins and related molecules, pannexins, play a role in tumorigenesis
in urinary bladder cancer [14]. Since these connexins build gap junctions, their involvement in
tumorigenesis is most likely. Studies of human urinary carcinoma should include freeze-fracture and
freeze-fracture immune-labelling to elucidate the role of gap junctions in this type of tumor.
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